Last reviewed · How we verify

NCT07192263

Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus

Not yet recruiting Phase 3 Last updated 25 September 2025
What this trial tests

Phase 3 trial testing IN-B00009 in Obesity &Amp; Overweight in 300 participants. Not yet recruiting.

Timeline
22 September 2025
Primary endpoint
31 December 2026
30 September 2027

Quick facts

Lead sponsorHK inno.N Corporation
PhasePhase 3
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment300
Start date22 September 2025
Primary completion31 December 2026
Estimated completion30 September 2027

Drugs / interventions tested

Conditions studied

Sponsor

HK inno.N Corporation — full company profile →

Who can join

Adults 19 to 75, any sex, with Obesity &Amp; Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 3 study is designed to evaluate the efficacy and safety of IN-B00009 injection in adults with obesity or overweight without diabetes mellitus

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity &Amp; Overweight

Currently open trials in the same condition.

Other HK inno.N Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07192263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing